BSX adds a niche

Article Excerpt

BOSTON SCIENTIFIC, $54.10, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (bostonscientific.com; Shares o/s: 1.5 billion; Market cap: $77.7 billion; No divds.) continues to add to its portfolio of medical devices used in minimally invasive procedures. The company will now pay $850 million (plus future performance payments) to buy private medical tech company Relievant Medsystems. Relievant’s Intracept system is the only U.S. FDA-approved treatment for vertebrogenic pain—a form of chronic lower back pain. Boston Scientific’s outlook is positive. In the past few months, it has gained regulatory approvals for several new products across all business categories. Ongoing clinical trials and an active development pipeline should generate further growth opportunities—not to mention timely acquisitions like Relievant. Boston Scientific is a buy. buy…